Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 20...
Read moreExecutive Summary Rare disease assessments rely on specialist clinical and patient expertise to inte...
Read moreAs NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...
Read morePrice ambition is only defensible when the evidence can carry it Manufacturers can no longer r...
Read morePricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...
Read moreThe first EU Joint Clinical Assessment (JCA) has now been published, providing the first practical i...
Read more